Women were randomly assigned to receive either ixabepilone ( 40 mg/m ( 2 ) ) every 21 days ( n = 40 ) , or ixabepilone ( 40 mg/m ( 2 ) ) every 21 days with cetuximab ( 400 mg/m ( 2 ) loading dose , followed by 250 mg/m ( 2 ) ) once weekly ( n = 39 ) .